5th Circuit Weighs Restricting Mail-Order Abortion Pills as Trump DOJ Sidesteps Safety Defense

Since the 5th Circuit heard oral arguments September 9 in Louisiana v. FDA, the three-judge panel has not issued a ruling, and a separate reproductive-health case was resolved in the meantime: a federal court in Pennsylvania dismissed a lawsuit challenging the Trump administration's overhaul of Title X family planning funding on September 18.

Both cases sit inside the same broader fight over abortion access four years after the Supreme Court overturned Roe v. Wade. Neither is settled.

What's at Stake in Louisiana v. FDA

Louisiana wants the FDA to reinstate a pre-2023 rule requiring mifepristone to be dispensed in person at a clinic or hospital, not mailed after a telehealth visit. Mifepristone is used in roughly 63% of U.S. abortions, according to MedPage Today, and CNN puts medication abortion overall at two-thirds of all U.S. abortions. About 28% of abortion patients now use telemedicine rather than an in-person visit, per MedPage Today.

Louisiana Solicitor General Ben Aguiñaga told the panel, according to the Epoch Times, that "there's no dispute that Louisiana is experiencing 1,000 abortions a month due to mifepristone mailed into the state." A survey conducted for the Society of Family Planning, a group that supports legal abortion access, estimated 770 to 900 Louisiana women a month obtained abortion pills this way in 2025, Breitbart reported.

Louisiana's underlying argument, as Aguiñaga framed it in the Austin Chronicle's account, is one of state sovereignty: the state says it can't enforce its own near-total abortion ban if federal rules let providers in other states mail pills across its border. That's a real and legitimate grievance for a state that has already indicted out-of-state doctors for prescribing mifepristone to its residents, per the Epoch Times, and the coercion allegation from co-plaintiff Rosalie Markezich, cited by Breitbart, is precisely the kind of harm abortion opponents argue the mail-order system makes harder to prevent.

But most of Wednesday's roughly 100 minutes, according to CNN, went to a narrower question: does Louisiana even have legal standing to sue over a federal regulation it can't show directly caused abortions inside its own borders? Judge Priscilla Richman, a George W. Bush appointee, told Aguiñaga she was "having trouble finding anywhere in the record that the FDA has approved the mailing of this drug into states where it's unlawful to do that." Judges Stephen Higginson and Dana Douglas, appointed by Barack Obama and Joe Biden respectively, pressed on whether "too many independent actors" break the chain between the FDA's rule and any harm to Louisiana, the Epoch Times reported.

The Trump Justice Department is not defending mifepristone's safety on the merits. DOJ attorney Daniel Winik argued the standing problem alone was reason enough to toss the case, while declining to answer judges' questions about Louisiana's substantive claims, CNN reported. That's a deliberate legal strategy, not indifference to the underlying politics, but it means the administration tasked with regulating the drug isn't in this fight defending it as safe.

Drug manufacturers Danco Laboratories and GenBioPro, both named as defendants, are making that safety case themselves, per the Austin Chronicle, pointing to research they say shows in-person dispensing is medically unnecessary.

The Legal Traffic Jam

This is one of three active lawsuits trying to roll back FDA's mifepristone rules. Florida and Texas are challenging the drug's original 2000 approval and everything since. Idaho, Kansas, and Missouri are targeting regulations dating to 2016. Louisiana's case, aimed specifically at the 2023 telehealth and pharmacy-dispensing rule, is furthest along, according to MedPage Today.

At the same time, two district courts have ordered the FDA to reconsider whether its mifepristone restrictions are too tight, not too loose, MedPage Today reported, in lawsuits brought by abortion providers who say the drug's low-risk profile doesn't justify the remaining REMS requirements. The FDA, under the Trump administration, is conducting its own safety review that could move in either direction.

Whatever the 5th Circuit decides, it won't change anything immediately. The Supreme Court blocked any rule changes in a May 2026 emergency order after the same appeals court had briefly sided with Louisiana, and that stay stays in effect until the justices take the case up again, CNN and the Austin Chronicle both reported. Every legal observer quoted across these outlets, regardless of ideological lean, expects this to end up back at the Supreme Court.

Title X Ruling Adds a Second Front

The September 18 dismissal of NFPRHA v. Kennedy is a separate legal track but part of the same fight over reproductive health policy. The National Family Planning & Reproductive Health Association and a Pennsylvania affiliate had sued HHS Secretary Robert F. Kennedy Jr. over a fiscal year 2027 funding notice they said was designed to push out qualified Title X providers in favor of grantees aligned with the administration's political priorities. NFPRHA president Clare Coleman said the group will keep prioritizing "evidence-based best practices" over what she called demands for "ideological alignment," according to the ACLU, which represented the plaintiffs. The court's dismissal, which the ACLU says opens the door to changes affecting millions of low-income patients' access to contraception, cancer screening, and STI testing, was not accompanied by a detailed public ruling in the sources available.

No ruling has been issued in Louisiana v. FDA as of September 21. The panel gave no indication of timing, and both sides are bracing for the case to land at the Supreme Court a second time.